microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Vanessa Desantis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Pharmacology Section, University of Bari Aldo Moro Medical School, 70124 Bari, Ita…. Hauptthemen laut MEDLINE: MicroRNAs, Atrial Fibrillation, Vascular Diseases, Atrial Remodeling. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The pathophysiology of atrial fibrillation (AF) may involve atrial fibrosis/remodeling and dysfunctional endothelial activities. Despite the currently available treatment approaches, the progression of AF, its recurrence rate, and the high mortality risk of related complications underlay the need for more advanced prognostic and therapeutic strategies. There is increasing attention on the molecular mechanisms controlling AF onset and progression points to the complex cell to cell interplay that triggers fibroblasts, immune cells and myofibroblasts, enhancing atrial fibrosis. In this scenario, endothelial cell dysfunction (ED) might play an unexpected but significant role. microRNAs (miRNAs) regulate gene expression at the post-transcriptional level. In the cardiovascular compartment, both free circulating and exosomal miRNAs entail the control of plaque formation, lipid metabolism, inflammation and angiogenesis, cardiomyocyte growth and contractility, and even the maintenance of cardiac rhythm. Abnormal miRNAs levels may indicate the activation state of circulating cells, and thus represent a specific read-out of cardiac tissue changes. Although several unresolved questions still limit their clinical use, the ease of accessibility in biofluids and their prognostic and diagnostic properties make them novel and attractive biomarker candidates in AF. This article summarizes the most recent features of AF associated with miRNAs and relates them to potentially underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision and Regenerative Medicine and Ionian Area, Pharmacology Section, University of Bari Aldo Moro Medical School, 70124 Bari, Italy.
- General Hospital "F. Miulli" Acquaviva delle Fonti, 70021 Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area, Unit of Internal Medicine and Clinical Oncology, University of Bari Aldo Moro Medical School, 70124 Bari, Italy.
ORCID-Profile: Vanessa Desantis, Maria Assunta Potenza, Sebastiano Cicco, Antonio Giovanni Solimando, Angelo Vacca, Monica Montagnani
Zitieren
APA
Desantis, V., Potenza, M. A., Sgarra, L., Nacci, C., Scaringella, A., Cicco, S., Solimando, A. G., Vacca, A., & Montagnani, M. (2023). microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065307
Vancouver
Desantis V, Potenza MA, Sgarra L, Nacci C, Scaringella A, Cicco S, et al. microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065307
BibTeX
@article{Desantis2023,
author = {Desantis, Vanessa and Potenza, Maria Assunta and Sgarra, Luca and Nacci, Carmela and Scaringella, Antonietta and Cicco, Sebastiano and Solimando, Antonio Giovanni and Vacca, Angelo and Montagnani, Monica},
title = {microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065307}
}
EUVIMED